TY - JOUR T1 - Validation of smartphone-based assessments of depressive symptoms using the Remote Monitoring Application in Psychiatry (ReMAP) JF - medRxiv DO - 10.1101/2020.08.27.20183418 SP - 2020.08.27.20183418 AU - Janik Goltermann AU - Daniel Emden AU - Elisabeth J. Leehr AU - Katharina Dohm AU - Ronny Redlich AU - Udo Dannlowski AU - Tim Hahn AU - Nils Opel Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/01/2020.08.27.20183418.abstract N2 - Smartphone-based symptom monitoring has gained increased attention in psychiatric research as a cost-efficient tool for prospective and ecologically valid assessments based on participants’ self-reports. However, a meaningful interpretation of smartphone-based assessments requires knowledge on their psychometric properties; especially their validity. Here, we conducted a systematic investigation of the validity of smartphone-based assessments of affective symptoms by using the smartphone app Remote Monitoring Application in Psychiatry (ReMAP). Beck Depression Inventory (BDI), and single-item mood and sleep information was assessed via the ReMAP app and validated with stationary (nonsmartphone) BDI scores and clinician-rated depression severity using the Hamilton Depression Rating Scale (HDRS).We found overall high comparability between smartphone-based and stationary BDI scores (ICC=.921, p<.001, n=173). Smartphone-based BDI further correlated with stationary HDRS ratings of depression severity (r=.783, p<.001, n=51). Higher agreement between smartphone and stationary assessments was found in affective disorder patients as compared to healthy controls, and anxiety disorder patients. Highly comparable agreement between delivery formats was found across age and gender groups. Similarly, smartphone-based single-item self-ratings of mood correlated with BDI sum scores (r=-.538, p<.001, n=168), while smartphone-based single-item sleep duration correlated with the sleep item of the BDI (r=-.310, p<.001, n=166).The present findings demonstrate that smartphone-based monitoring of depressive symptoms via the ReMAP app provides valid assessments of depressive symptomatology and therefore represents a useful tool for prospective digital phenotyping in affective disorder patients in clinical and research applications.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding was provided by the DFG - Projectnumber 44541416-TRR 58 (CRC-TRR58, Projects C09 and Z02 to Udo Dannlowski) and the Interdisciplinary Center for Clinical Research (IZKF) of the medical faculty of Muenster (Grant Dan3/012/17 to Udo Dannlowski and SEED 11/19 to NO), as well as the Innovative Medizinische Forschung (IMF) of the medical faculty of Muenster (Grants OP121710 to NO and TH; LE121703 and LE121904 to EJL). Further DFG funding in the context of the Forschungsgruppe/Research Unit FOR2107 was received by: Tilo Kircher (speaker FOR2107; DFG grant numbers KI 588/14-1, KI 588/14-2, KI 588/15-1, KI 588/17-1), Udo Dannlowski (co-speaker FOR2107; DA 1151/5-1, DA 1151/5-2, DA 1151/6-1), Axel Krug (KR 3822/5-1, KR 3822/7-2), Igor Nenadic (NE 2254/1-2), Carsten Konrad (KO 4291/3-1), Marcella Rietschel (RI 908/11-1, RI 908/11-2), Markus Noethen (NO 246/10-1, NO 246/10-2), Stephanie Witt (WI 3439/3-1, WI 3439/3-2), Andreas Jansen (JA 1890/7-1, JA 1890/7-2), Tim Hahn (HA 7070/2-2, HA7070/3, HA7070/4), Bertram Mueller-Myhsok (MU1315/8-2), Astrid Dempfle (DE 1614/3-1, DE 1614/3-2), Petra Pfefferle (PF 784/1-1, PF 784/1-2), Harald Renz (RE 737/20-1, 737/20-2), Carsten Konrad (KO 4291/4-1). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethik-Kommission der Aerztekammer Westfalen-Lippe und der Westfaelischen Wilhelms-Universitaet, Muenster, Germany All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDerived data supporting the findings of this study are available from the corresponding author on request. ER -